Navigation Links
Rib-X Pharmaceuticals Expands License Agreement with Yale University on New Ribosome Technology
Date:12/8/2009

NEW HAVEN, Conn., Dec. 8 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel drugs for the treatment of serious multi-drug-resistant infections, announced today it has entered into a further license agreement with Yale University in the area of ribosome and antibiotic structure and function. Under the agreement, Rib-X will further explore the high resolution crystal structure of new ribosome technology elucidated by Dr. Thomas Steitz and colleagues at Yale.

Dr. Steitz, who was recently awarded the Nobel Prize in Chemistry for 2009 by The Royal Swedish Academy of Sciences, is Sterling Professor of Molecular Biophysics and Biochemistry at Yale University and a Howard Hughes Medical Institute Investigator. He is also a Rib-X Co-Founder and Chair of the Scientific Advisory Board of the Company.

"This high resolution structure will become an important additional tool in the discovery of new antibiotic agents," said Susan Froshauer, Ph.D., Rib-X's President and CEO. "This further license is a natural extension of our relationship with Yale, and builds upon Dr. Steitz's Nobel Prize winning work and, in turn, will increase our understanding, on an atomic level, of the binding properties of antibiotics to the ribosome."

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company currently has two drug candidates: delafloxacin, which is ready to enter Phase 3 clinical trials, and radezolid, whose oral form has been tested for safety and efficacy in two Phase 2 trials. Delafloxacin is a broad-spectrum fluoroquinolone with potent activity against quinolone-resistant Gram-positive bacteria, including methicillin-resistant S. aureus (MRSA). Radezolid, a new oxazolidione dis
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
2. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
3. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
4. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
6. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
7. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
8. Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph.D., Awarded the 2009 Nobel Prize in Chemistry
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... Research and Markets( ... "Deciphering Global Major Pharmaceutical Companies, New Outsourcing ... It has been publicly recognized that ... a series of challenges in the recent years. ... overcapacities in small molecule product manufacturing; increasingly challenging ...
(Date:7/7/2015)... NEWTOWN, Pennsylvania , 7. Juli 2015 /PRNewswire/ ... Spezial-Dienstleistungen und -Technik für klinische Studien, gab heute ... (Medici) ein führendes Unternehmen bei Gewinnung und Erhalt ... umfasst die Tochtergesellschaften MediciGlobal , Ltd. und ... L2FU® auch einen Dienst zum Auffinden von ...
(Date:7/7/2015)... , July 7, 2015   InspireMD, Inc. ... a leader in embolic protection systems ("EPS"), today ... Protection System integrated with MicroNet ™ has ... Stent New Product Innovation Award.  Through active market ... analysts and consultants recognize the successful introduction of ...
Breaking Medicine Technology:Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 2Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 3BioClinica übernimmt MediciGroup 2BioClinica übernimmt MediciGroup 3BioClinica übernimmt MediciGroup 4InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award 2InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award 3InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award 4InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award 5
... NASHVILLE, Tenn., Aug. 4, 2011 Cumberland Pharmaceuticals Inc ... focused on hospital acute care and gastroenterology markets, today announced ...   For the three months ended June 30, 2011, net ... the prior year period. The growth in revenue was due ...
... Calif., Aug. 4, 2011 DURECT Corporation (Nasdaq: ... ended June 30, 2011. Total revenues increased to $7.8 million ... million for the three months ended June 30, 2010.  Net ... $5.2 million, compared to a net loss of $6.3 million ...
Cached Medicine Technology:Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results 2Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results 3Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results 4Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results 5Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results 6Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results 7Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results 8Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results 9Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results 10Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results 11Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results 12DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs 2DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs 3DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs 4DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs 5DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs 6DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs 7DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs 8
(Date:7/7/2015)... ... ... Quadrino Law Group is pleased to announce the relocation of the firm's ... new facility is a state of the art building, located with easy access to ... and founder, said, "We are pleased to service our clients from such a premier ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... global provider of advanced delivery technologies and development solutions for drugs, biologics ... licensing agreement with Excelimmune, Inc. to access its antibody combination therapy (ACT) ...
(Date:7/7/2015)... ... , ... Summer is a great time to get outside and be active. ... safety tips. , Jean Tapley, senior wellness coordinator at Amica, suggests the following seven ... Start slowly. Going from no activity to several hours of activity can potentially ...
(Date:7/7/2015)... ... July 07, 2015 , ... On Saturday, May 16th, 2015, the ... Manistee Golf and Country Club. Best Drug Rehabilitation staff members were delighted to join ... underprivileged children. Kiwanis International, the parent of the Manistee Kiwanis Club, is a global ...
(Date:7/7/2015)... ... July 07, 2015 , ... FSAstore.com today announced the launch ... holders. HSAstore.com makes it simple to use, spend and manage HSA funds with innovative ... accounts. , According to a report by Devenir , approximately 13.8 million ...
Breaking Medicine News(10 mins):Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2Health News:Amica Insurance Has 7 Summer Safety Tips 2Health News:Best Drug Rehabilitation Team Participates in Kiwanis Club Golf Outing Fundraiser 2Health News:Introducing HSAstore.com: A New E-commerce Site for Health Savings Account Eligible Products and Services 2Health News:Introducing HSAstore.com: A New E-commerce Site for Health Savings Account Eligible Products and Services 3
... A chronic shortage of health workers in developing nations ... tuberculosis and malaria// , World Health Organization Director-General Margaret ... Health Day on April 7. ,Thousands of ... nations in search of higher paying jobs in wealthier ...
... and very poor, has banned the life-threatening practice of female ... ,Anybody involved in female genital mutilation (FGM) would be punished ... ,The move follows a campaign against the practice by the ... of Eritrean women are circumcised. ,'Female circumcision ...
... uncomfortable symptoms and help women feel better while going through ... in a woman's life when her menstrual cycle, associated with ... age 45. ,The four-month study by Penn ... 160 women, dividing them into three groups. ,One ...
... V’s Rabies monoclonal antibody (mAb) product has entered a ... launching// a similar study in the US. ... for the post-exposure prophylaxis of rabies, using Crucell’s MAbstract ... is closely linked to the initial phase I study ...
... Pharmaceuticals has treated the first patient in a new ... of Ceflatonin// (homoharringtonine or HHT) in patients with Chronic ... to treatment with two or more prior tyrosine kinase ... to complement the ongoing registration-directed clinical trial in CML ...
... New York City’s Department of Health and Mental Hygiene is ... AIDS to get circumcised in light of the World Health ... prevent the disease. ,In the United States, “New York ... R. Frieden, the city’s health commissioner, said in an interview. ...
Cached Medicine News:Health News:Eritrea Bans Female Circumcision 2Health News:Crucell's Rabies MAb Enters Phase I Trial in India 2Health News:New York City Plans to Promote Circumcision 2
... single liquid stable reagent offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The proprietary ... reagent provides a long shelf life ...
... powder reagent once reconstituted offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The proprietary ... reagent provides a long shelf life ...
LCD chart display...
Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
Medicine Products: